When insurance delays mean poorer prognosis
Mikkael Sekeres, MD, MS, shares a story illustrating that even when patients, doctors and health systems emphasize time to treat, insurance processes can delay treatment. He writes:
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“But I wondered whether the delays in his treatment hadn’t worsened his chance of being cured. I understand that, particularly in this age of breathtakingly expensive cancer treatment, there is a need for checks and balances on our treatment recommendations and their potential benefit. That public health perspective seemed awfully shortsighted, though, when I had to face my patient and his dad each week as his leukemia threatened to come raging back.”
Read the entire New York Times column.
Dr. Sekeres is Director of Cleveland Clinic Cancer Center’s Leukemia Program.
Advertisement
Advertisement
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust